Sanofi Should Pay Mannkind For Doing Little To Nothing For Afrezza & Walking Away
There is clearly no doubt Sanofi did not meet their good faith effort obligation under the 2014 Global Licensing Deal and should be forced to compensate Mannkind paying cash to Mannkind and forgiving debt owed by Mannkind to Sanofi. Here is Sanofi is guilty of not doing....
1) Sanofi did little to create market awareness across the entire United States for Afrezza
2) Sanofi's spending was anemic promoting & educating Afrezza to patients and healthcare professionals
3) Sanofi commercialization budget & support was inferior in proportion to what was done for Toujeo
3) Sanofi did nothing in the clinic to pursue an improved label for Afrezza
4) Sanofi REMS efforts were minimal choosing a limited pediatric study & delaying lung safety study
5) Sanofi did nothing outside get Afrezza approved & selling outside the United States
6) Sanofi's DTC Campaign rolled out in September was a joke with only a few print ads placed
7) Sanofi did little to promote Afrezza during public forums like investor & healthcare conferences
8) Sanofi completely ignored the great benefits early adopters were seeing and talking about in the real world
9) Sanofi's sales organization did little face to face place of business calls to healthcare providers
10) Sanofi's sales organization did little face to fact place of business calls to pharmacists
11) Sanofi consistently downplayed or ignored Afrezza during all conference calls and presentations
12) Sanofi's marketing budget for Afrezza vs. Toujeo was disproportional favoring Toujeo
13) Sanlofi's intentionally priced Afrezza at a premium opposite Mannkind's recommendation
14) Sanofi's development/clinical effort for Afrezza vs. Toujeo was disproportional favoring Toueo
15) Sanofi's promised to have Afrezza available in Israel quickly and it never happened
16) Sanofi did not allocate the time, money and resources to promote Afrezza game changing benefits
17) Sanofi's spending & people support for Afrezza was less compared to other drugs
finance.yahoo.com/mbview/threadview/?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&tid=1454253323072-45cb1bd9-d71e-43bd-a6b2-1291bec7b01d&tls=la%2Cd%2C3%2C3By Kevinmik
IMHO the biggest disservice SNY did to MNKD shareholders, a slight that should be pursued in court, is 1) poorly supporting afrezza commercialization, while 2) assuring us in a very misleading fashion that this was all ok because it was a controlled launch.
IMO this is nothing short of willfully misrepresenting marketing efforts at the expense of MNKD shareholders.
By dtrouble1003